港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

长风药业

23.420

-0.700-2.90%

成交量：103.95万

成交额：2,546.81万

市值：96.26亿

市盈率：411.79

高：26.300

开：24.800

低：23.380

收：24.120

52周最高：48.800

52周最低：20.300

股本：4.11亿

香港流通股本：3.02亿

量比：0.26

换手率：0.34%

股息：- -

股息率：- -

每股收益(LYR):0.057

净资产收益率：-5.62%

总资产收益率：-5.30%

市净率：8.87

市盈率(LYR):411.79

市销率: 14.07

数据加载中...

总览公司新闻资讯公告

长风药业(02652)与京东健康签署战略合作

长风药业与京东健康达成三年战略合作新品线上首发平台独家落户

长风药业预计2025年经调整净利3000万元至3500万元

长风药业(02652)预计2025年度经调整净利润约3000万元至3500万元，业务运营稳健，创新研发持续推进

长风药业：预计2025年度净利润将降至约0.02亿–0.03亿元，同比下滑约86%–91%

长风药业年度业绩预告：主力产品CF017均价下滑拖累盈利

长风药业(02652)股价显著上升14.541%，现价港币$28.2

阿斯达克财经

重大突破！长风药业(2652.HK)全球创新改良机制肺动脉高压新药获IND受理，精准给药平台再立里程碑

长风药业大涨超41%！该公司自主研发的肺动脉高压新药IND获受理，填补国内治疗PH-ILD领域空白

老虎资讯综合

港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理填补国内治疗PH-ILD领域空白

长风药业(02652)自主研发的吸入粉雾剂候选药物ICF001的IND申请获NMPA受理

全球改良机制！长风药业(02652)肺动脉高压新药IND获受理精准递送平台创新转化再获里程碑

长风药业(02652)股价下跌5.036%，现价港币$23.76

阿斯达克财经

重磅产品获批临床！500亿过敏性鼻炎用药市场将迎变局

长风药业盘中异动早盘股价大涨5.32%

长风药业03月09日主力净流出120.1万元散户资金买入

港股公告掘金 | 蒙牛乳业预计年度股东应占利润将约为14亿元至 16亿元

长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准

智通财经网

长风药业获NMPA批准开展盐酸奥洛他定与糠酸莫米松一水合物鼻喷雾剂临床试验

长风药业(02652)获纳入沪港通及深港通的港股通标的证券名单

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02652/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02652","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"长风药业","latestPrice":23.42,"timestamp":1774253287810,"preClose":24.12,"halted":0,"volume":1039500,"delay":0,"changeRate":-0.02902155887230511,"floatShares":302000000,"shares":411000000,"eps":0.056874,"marketStatus":"已收盘","change":-0.7,"latestTime":"03-23 16:08:07","open":24.8,"high":26.3,"low":23.38,"amount":25468140,"amplitude":0.121061,"askPrice":23.44,"askSize":15000,"bidPrice":23.42,"bidSize":39000,"shortable":0,"etf":0,"ttmEps":0.073,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":24.12,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"volumeRatio":0.264413,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","floatShares":302000000,"roa":"-5.30%","roe":"-5.62%","lyrEps":0.056874,"volumeRatio":0.264413,"shares":411000000,"dividePrice":0,"high":26.3,"amplitude":0.121061,"preClose":24.12,"low":23.38,"week52Low":20.3,"pbRate":"8.87","psRate":"14.07","week52High":48.8,"institutionHeld":0,"latestPrice":23.42,"committee":0.444444,"eps":0.056874,"divideRate":0,"volume":1039500,"delay":0,"ttmEps":0.073,"open":24.8,"prevYearClose":35,"prevWeekClose":24.12,"prevMonthClose":39,"prevQuarterClose":35,"fiveDayClose":27.92,"twentyDayClose":36.78,"sixtyDayClose":34.86,"earningDate":1774800000000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02652\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02652\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02652\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02652\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02652","date":"2026-03-20","current":320.821918,"percent":0.018182,"low":-293.764894,"twenty":397.81132,"median":454.320794,"eighty":480.840623,"high":513.213561,"avg":434.05282,"sd":84.184845,"marketCap":9924943114},"quantilePoints":[{"date":"2025-10-10","current":420.512992,"twenty":-8.053739,"median":420.512992,"eighty":438.465035,"marketCap":12738371726},{"date":"2025-10-17","current":400.969089,"twenty":380.917252,"median":393.18793,"eighty":412.695431,"marketCap":12136883281},{"date":"2025-10-24","current":382.04749,"twenty":383.954109,"median":395.798507,"eighty":407.879105,"marketCap":11568353106},{"date":"2025-10-31","current":411.638127,"twenty":385.87135,"median":395.798507,"eighty":410.009732,"marketCap":12482945126},{"date":"2025-11-07","current":380.629431,"twenty":385.87135,"median":397.412529,"eighty":410.009732,"marketCap":11535394836},{"date":"2025-11-14","current":413.442652,"twenty":386.82146,"median":399.24986,"eighty":411.625005,"marketCap":12565340803},{"date":"2025-11-21","current":474.663516,"twenty":387.596392,"median":401.654037,"eighty":419.1227,"marketCap":14419243545},{"date":"2025-11-28","current":513.213561,"twenty":390.697015,"median":408.734506,"eighty":451.19497,"marketCap":15646939138},{"date":"2025-12-05","current":509.365027,"twenty":391.797785,"median":411.605323,"eighty":487.699676,"marketCap":15556303893},{"date":"2025-12-12","current":478.26383,"twenty":394.588712,"median":413.442652,"eighty":485.541496,"marketCap":14633472306},{"date":"2025-12-19","current":468.273561,"twenty":396.041553,"median":429.606948,"eighty":482.974301,"marketCap":14361566570},{"date":"2025-12-24","current":469.497744,"twenty":396.770692,"median":439.211078,"eighty":482.563912,"marketCap":14443962248},{"date":"2026-01-02","current":452.984556,"twenty":397.492287,"median":451.385447,"eighty":481.570975,"marketCap":13990786022},{"date":"2026-01-09","current":417.797013,"twenty":398.674444,"median":438.955991,"eighty":480.057858,"marketCap":12936121351},{"date":"2026-01-16","current":442.060347,"twenty":399.985866,"median":432.778937,"eighty":478.730146,"marketCap":13731858722},{"date":"2026-01-23","current":466.639698,"twenty":400.772068,"median":439.902936,"eighty":477.371374,"marketCap":14481468286},{"date":"2026-01-30","current":480.840623,"twenty":401.791027,"median":446.916666,"eighty":477.757159,"marketCap":14990389486},{"date":"2026-02-06","current":464.022312,"twenty":403.190746,"median":452.185001,"eighty":477.033593,"marketCap":14502764350},{"date":"2026-02-13","current":452.173894,"twenty":406.744138,"median":454.320794,"eighty":475.6532,"marketCap":14213623359},{"date":"2026-02-20","current":472.094804,"twenty":408.734506,"median":454.916554,"eighty":476.776403,"marketCap":14818441932},{"date":"2026-02-27","current":505.751529,"twenty":411.273773,"median":459.838493,"eighty":479.42962,"marketCap":16048983093},{"date":"2026-03-06","current":445.246344,"twenty":411.572519,"median":460.887466,"eighty":481.94993,"marketCap":14015073071},{"date":"2026-03-13","current":299.287031,"twenty":402.338985,"median":457.528006,"eighty":481.000215,"marketCap":9464083401},{"date":"2026-03-20","current":315.053976,"twenty":397.81132,"median":454.320794,"eighty":480.840623,"marketCap":9924943114}],"updateTime":1774258404880},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02652\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621747605","title":"长风药业(02652)与京东健康签署战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747605","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621747605?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 08:14","pubTimestamp":1774224870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布公告，本公司于2026年3月20日与京东健康股份有限公司正式签署战略合作协议。根据战略合作协议，京东健康将作为本公司未来三年多款呼吸及鼻科领域重磅新产品的线上独家首发合作平台。鉴于上述疾病在中国的患者基数较大且具有长期管理的特征，董事会认为，订立战略合作协议符合本公司及其股东的整体利益。本次合作预期有助于提升本公司产品的患者可及性及新产品商业化效率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1589","BK1571","LU0456827905.SGD","BK1615","BK1142","BK1591","LU0051755006.USD","BK1247","BK1515","BK1583","SGXZ62798434.SGD","02652","SGXZ86797644.SGD","86618","06618"],"gpt_icon":0},{"id":"1168787711","title":"长风药业与京东健康达成三年战略合作 新品线上首发平台独家落户","url":"https://stock-news.laohu8.com/highlight/detail?id=1168787711","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168787711?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 08:05","pubTimestamp":1774224320,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司（股票代码：02652）近日与京东健康签署为期三年的战略合作协议。根据协议内容，京东健康将成为长风药业未来三年内主要新产品的独家线上首发平台。此次合作将依托京东健康的数字化营销能力和全渠道资源，助力长风药业创新产品快速触达终端消费者。双方将通过数据驱动的精准营销策略，共同探索医药健康领域的新零售模式，为患者提供更便捷的药品可及性服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"gpt_icon":0},{"id":"2621719212","title":"长风药业预计2025年经调整净利3000万元至3500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719212","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621719212?lang=zh_cn&edition=fundamental","pubTime":"2026-03-22 16:04","pubTimestamp":1774166640,"startTime":"0","endTime":"0","summary":"3月20日，长风药业（02652）发布公告，预计2025年收入将在4.1亿元至4.5亿元之间，而2024年收入约为6.08亿元，显示出显著下降。根据国际财务报告准则(IFRS)，2025年股东应占溢利预计在200万元至300万元之间，而2024年则为约2109万元。经调整净利润（非国际财务报告准则指标）预计为3000万元至3500万元，较2024年的约5187万元下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679733937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2621059758","title":"长风药业(02652)预计2025年度经调整净利润约3000万元至3500万元，业务运营稳健，创新研发持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059758","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621059758?lang=zh_cn&edition=fundamental","pubTime":"2026-03-21 00:39","pubTimestamp":1774024786,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得收入介于人民币4.10亿元至4.50亿元;根据国际财务报告准则会计准则，股东应占溢利介于人民币200万元至300万元;经调整净利润为介于人民币3000万元至3500万元。公司或会视市场情况及资金安排，在遵守上市规则及适用法规的前提下，考虑进一步回购H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652"],"gpt_icon":0},{"id":"1121931516","title":"长风药业：预计2025年度净利润将降至约0.02亿–0.03亿元，同比下滑约86%–91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121931516","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121931516?lang=zh_cn&edition=fundamental","pubTime":"2026-03-20 22:37","pubTimestamp":1774017454,"startTime":"0","endTime":"0","summary":"长风药业3月20日发布盈利预警，预计2025年度各项业绩指标将出现明显下滑。营业收入：2025年预计为4.10亿–4.50亿元，较2024年的约6.08亿元下降约26%–33%。按国际财务报告准则计，股东应占净利润预计为0.02亿–0.03亿元，较2024年的约0.21亿元下降约86%–91%。剔除上市费用及以股份为基础的薪酬后，2025年调整后净利润预计为0.30亿–0.35亿元，低于2024年的约0.52亿元，降幅约33%–42%。公司指出，目前整体业务运营保持正常，年度审计结果将在2026年3月底正式公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1128591258","title":"长风药业年度业绩预告：主力产品CF017均价下滑拖累盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1128591258","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128591258?lang=zh_cn&edition=fundamental","pubTime":"2026-03-20 22:32","pubTimestamp":1774017134,"startTime":"0","endTime":"0","summary":"受核心产品CF017及其他主要药品平均售价下调影响，长风药业（CF Pharmtech）预计本财年盈利水平将面临下行压力。产品价格策略的调整虽有助于提升市场渗透率，但短期内将对整体营收规模及利润率产生显著冲击。\n公司表示将持续优化生产成本结构，通过供应链协同与工艺创新抵消部分价格波动带来的负面影响。管理层强调将加速新品研发管线推进，以期通过产品组合升级重塑增长动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2620002554","title":"长风药业(02652)股价显著上升14.541%，现价港币$28.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2620002554","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620002554?lang=zh_cn&edition=fundamental","pubTime":"2026-03-18 09:35","pubTimestamp":1773797700,"startTime":"0","endTime":"0","summary":"[上升股]长风药业(02652) 股价在上午09:35比前收市价显著上升14.541%，现股价为港币$28.2。至目前为止，今日最高价为$28.2，而最低价为$24.62。总成交量为43.4万股，总成交金额为港币$1.165千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318147/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318147/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02652"],"gpt_icon":0},{"id":"1123563012","title":"重大突破！长风药业(2652.HK)全球创新改良机制肺动脉高压新药获IND受理，精准给药平台再立里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1123563012","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123563012?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 18:13","pubTimestamp":1773656000,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司（股票代码：2652.HK）近日迎来重大进展，其针对肺动脉高压（PAH）开发的全球创新改良机制新药已获得临床试验申请（IND）受理。这一突破性进展标志着公司在精准药物递送平台技术领域再攀新高，展现了其在创新药研发领域的强大实力。\n该新药凭借全球首创的改良机制，有望为肺动脉高压患者提供更优治疗方案。此次IND的成功受理，不仅验证了长风药业核心技术的先进性，更为后续临床开发奠定了坚实基础。公司精准给药平台持续输出创新成果，本次里程碑事件进一步巩固了其在细分领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab62decfe9624416502f0a5b97418c66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"gpt_icon":0},{"id":"1192376225","title":"长风药业大涨超41%！该公司自主研发的肺动脉高压新药IND获受理，填补国内治疗PH-ILD领域空白","url":"https://stock-news.laohu8.com/highlight/detail?id=1192376225","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192376225?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 10:30","pubTimestamp":1773628201,"startTime":"0","endTime":"0","summary":"3月16日，$长风药业$大涨超41%，该公司自主研发的肺动脉高压新药IND获受理，填补国内治疗PH-ILD领域空白消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001的快速推进，有望使其成为国内首个获批用于治疗PH-ILD的吸入药物，填补这一市场空白，同时为全球数十万计的患者带来生命的$曙光$。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab62decfe9624416502f0a5b97418c66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","LU0320765489.SGD","LU1989772923.USD","BK1191","BK4585","BK4580","LU0208291251.USD","LU0256863902.USD","LU1988902786.USD","BK4161","LU0070302665.USD","BK4588","LU0211331839.USD","LU1989772840.SGD","LU1064131342.USD","LU0256863811.USD","LU2264538146.SGD","LU0417517546.SGD"],"gpt_icon":1},{"id":"2619487098","title":"港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理 填补国内治疗PH-ILD领域空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2619487098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619487098?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 10:02","pubTimestamp":1773626554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，长风药业涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001的快速推进，有望使其成为国内首个获批用于治疗PH-ILD的吸入药物，填补这一市场空白，同时为全球数十万计的患者带来生命的曙光。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab62decfe9624416502f0a5b97418c66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765489.SGD","02652","IND","BK4588","LU1988902786.USD","BK4585","LU0070302665.USD","LU2264538146.SGD","BK4580","LU1989772840.SGD","BK4161","VXUS","LU1064131342.USD","LU0256863811.USD","BK1191","LU0256863902.USD","LU0208291251.USD","LU0211331839.USD","PH","LU1989772923.USD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2619882190","title":"长风药业(02652)自主研发的吸入粉雾剂候选药物ICF001的IND申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619882190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619882190?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 21:02","pubTimestamp":1773406944,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验申请已获中华人民共和国国家药品监督管理局受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。ICF001的首发适应症为动脉性肺动脉高压与间质性肺疾病相关肺动脉高压。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IND","02652"],"gpt_icon":0},{"id":"2619047168","title":"全球改良机制！长风药业(02652)肺动脉高压新药IND获受理 精准递送平台创新转化再获里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2619047168","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619047168?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 13:35","pubTimestamp":1773380142,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001 是一款基于前药机制实现长效作用的创新型吸入粉雾剂。该类药物在相关罕见及严重肺部疾病中已确立明确的临床价值及验证的重磅药物潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1191","02652"],"gpt_icon":1},{"id":"2619157827","title":"长风药业(02652)股价下跌5.036%，现价港币$23.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157827","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619157827?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 11:35","pubTimestamp":1773372900,"startTime":"0","endTime":"0","summary":"[下跌股]长风药业(02652) 股价在上午11:35比前收市价下跌5.036%，现股价为港币$23.76。至目前为止，今日最高价为$25.0，而最低价为$23.76。总成交量为25.5万股，总成交金额为港币$619.089万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603131799/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603131799/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2618490799","title":"重磅产品获批临床！500亿过敏性鼻炎用药市场将迎变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2618490799","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618490799?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:38","pubTimestamp":1773218312,"startTime":"0","endTime":"0","summary":"在高频复发且患者规模庞大等特征下，过敏性鼻炎催生了百亿元规模的药物市场。有数据显示，2024年—2028年，我国过敏性鼻炎用药行业市场规模由432.75亿元增长至500.9亿元。此外，该产品将与公司现有的过敏性鼻炎及慢性鼻窦炎产品组合形成互补，进一步增强公司在国内及全球市场的竞争优势。未来，随着国产创新产品不断涌现、研发技术持续迭代，我国过敏性鼻炎用药市场将迎来更广阔的发展空间，将为患者带来健康福音。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311164011a6b79a35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311164011a6b79a35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02652"],"gpt_icon":0},{"id":"2618941886","title":"长风药业盘中异动 早盘股价大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941886","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941886?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 09:51","pubTimestamp":1773193900,"startTime":"0","endTime":"0","summary":"2026年03月11日早盘09时51分，长风药业股票出现异动，股价急速拉升5.32%。截至发稿，该股报29.700港元/股，成交量15.85万股，换手率0.05%，振幅5.32%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。长风药业股票所在的药品行业中，整体跌幅为0.08%。其相关个股中，宝济药业-B、君圣泰医药-B、长风药业涨幅较大，振幅较大的相关个股有宝济药业-B、开拓药业-B、李氏大药厂，振幅分别为8.56%、7.41%、7.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311095140a6b6ad4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311095140a6b6ad4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2618675399","title":"长风药业03月09日主力净流出120.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675399","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618675399?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 16:15","pubTimestamp":1773044116,"startTime":"0","endTime":"0","summary":"03月09日, 长风药业股价跌13.39%，报收29.50元，成交金额5641.4万元，换手率0.63%，振幅27.01%，量比6.62。长风药业今日主力资金净流出120.1万元，上一交易日主力净流出0万元。该股近5个交易日下跌26.62%，主力资金累计净流出157.1万元；近20日主力资金累计净流出77.6万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161553a6b1b2f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161553a6b1b2f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02652"],"gpt_icon":0},{"id":"2618369053","title":"港股公告掘金 | 蒙牛乳业预计年度股东应占利润将约为14亿元至 16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618369053","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618369053?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 09:03","pubTimestamp":1773018197,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：阿得贝利单抗注射液获得药物临床试验批准通知书安井食品(02648)拟向河南子公司增资1.2亿元轩竹生物-B(02575)获纳入港股通股票名单派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果长风药业(02652)获纳入沪港通及深港通的港股通标的证券名单滨海投资(02886)获提供不超过4500万美元及1.73亿","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1769817096.USD","IE00B031HY20.USD","LU0315179316.USD","BK1237","BK1191","IE0032834883.USD","LU0287142896.SGD","LU0359201612.USD","LU1048588211.SGD","LU0370786039.SGD","02575","LU0251143458.SGD","LU0594300419.USD","LU1115378108.SGD","LU0211977185.USD","LU0672654166.SGD","LU0072462343.USD","BK1597","LU0259732245.USD","IE00B97KM107.HKD","LU2045819591.USD","VXUS","IE00B0169L03.USD","HK0000320264.USD","02652","HK0000306701.USD","LU1224709979.USD","SG9999002828.SGD","BK1521","IE0009570106.USD","IE00B29SXG58.USD","02319","LU0163747925.USD","LU0823426308.USD","LU0128522157.USD","VT","LU0348788117.USD","LU0588546209.SGD","IE0008368742.USD","LU0651946864.USD","LU0029875118.USD","LU0307460666.USD","LU1769817179.HKD","LU0650527681.SGD","IE00B031J352.USD","LU0359201885.HKD","LU2125910500.SGD","LU0737861699.HKD","LU0106959298.USD","BK1553"],"gpt_icon":0},{"id":"2618469288","title":"长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618469288","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618469288?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 07:48","pubTimestamp":1773013699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布公告，奥洛他定莫米松鼻喷雾剂的临床试验申请已获中华人民共和国国家药品监督管理局批准。公司是中国首家就该产品提交仿制药临床试验申请的企业。该CTA的获批标志着推进该产品进入临床试验阶段的里程碑。该产品的进展进一步印证了集团在复杂鼻喷雾制剂及药械整合方面的执行能力。集团将与NMPA保持积极沟通，并按照监管要求推进后续临床活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长风药业(02652)奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","02652"],"gpt_icon":0},{"id":"1122463913","title":"长风药业获NMPA批准开展盐酸奥洛他定与糠酸莫米松一水合物鼻喷雾剂临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1122463913","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122463913?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 07:45","pubTimestamp":1773013520,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司宣布，其研发的盐酸奥洛他定与糠酸莫米松一水合物鼻喷雾剂已获得国家药品监督管理局（NMPA）的临床试验申请批准。这一进展标志着该药物正式进入临床研究阶段，为公司产品管线增添了重要一员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2617806662","title":"长风药业(02652)获纳入沪港通及深港通的港股通标的证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617806662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617806662?lang=zh_cn&edition=fundamental","pubTime":"2026-03-08 18:41","pubTimestamp":1772966488,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业(02652)发布公告，根据上海证券交易所及深圳证券交易所发布的港股通标的证券名单调整公告，本公司H股已正式获纳入沪港通及深港通下的港股通标的证券名单，有关调整自2026年3月9日起生效。自生效日起，符合港股通准入条件的中国内地投资者将可透过沪港通及深港通下的港股通机制，交易本公司于香港联合交易所有限公司上市的H股。董事会预期，是次纳入将有助于扩大本公司的股东基础，提升本公司H股的交易流动性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VT","161027","BK1191","02652","VXUS","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":145,"code":"91000000","status":"200"}]}}